BOSTON and DURHAM, N.C., July 02, 2021 (GLOBE NEWSWIRE) -- Parexel, a leading global clinical research organization (CRO) focused on development and delivery of innovative new therapies to advance ...

EQT AB and Goldman Sachs Group Inc.’s investment arm agreed to buy contract-research organization Parexel International Corp. for $8.5 billion, including debt. Parexel runs clinical trials and ...

BOSTON, Aug. 14 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services organization, today announced ...

A pair of private equity firms are acquiring contract research organization (CRO) Parexel for $8.5 billion, the latest in a series of deals involving companies in this sector of life sciences.

Parexel, the Newton-based company that helps run clinical trials for the pharmaceutical industry, said Friday it would be bought by the Swedish private equity firm EQT and Goldman Sachs Asset ...

BOSTON, and DURHAM, N.C., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Parexel, a leading global clinical research organization (CRO) focused on development and delivery of innovative new therapies to ...

Parexel has launched an expanded Managed Access Programs service to streamline patients’ access to compassionate use of investigational medical products. The FDA allows companies to provide ...

Collaboration to pair artificial intelligence proficiencies with clinical research expertise. Parexel, a contract research organization (CRO), and Partex, a data-to-drugs pharma platform, have inked a ...

PAREXEL Consulting, a business unit of PAREXEL International (Nasdaq: PRXL) and a leading global life sciences consultancy serving the biopharmaceutical and medical device industries, today ...

The early phase clinical research unit on the 7th floor is one of four around the world run by Parexel, a multibillion dollar research organization. And Parexel just made a major investment in the ...